Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma

Affatato, Roberta; Carrassa, Laura; Chilà, Rosaria; Lupi, Monica; Restelli, Valentina; Damia, Giovanna

doi:10.3390/cancers12030672

Cited by 23 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLK1 activates the SAC signal when inhibited [ 216 ]. PLK1 expression has been connected with disease prognosis and sensitivity to chemotherapy in ovarian cancer, which presents a potential biomarker or therapeutic target in combating resistance [ 201 , 216 , 219 , 220 ]. Studies have shown that inhibiting PLK1 in the presence of PTX [ 201 , 216 ] resensitized ovarian cancer cells to PTX and reduced cell proliferation, as well as inducing apoptosis in HGSOC cells with CCNE1 amplification.…”

Section: Taxane Resistance In Ovarian Cancermentioning

confidence: 99%

Mechanisms of Taxane Resistance

Maloney

Hoover

Morejon-Lasso

et al. 2020

Cancers

View full text Add to dashboard Cite

The taxane family of chemotherapy drugs has been used to treat a variety of mostly epithelial-derived tumors and remain the first-line treatment for some cancers. Despite the improved survival time and reduction of tumor size observed in some patients, many have no response to the drugs or develop resistance over time. Taxane resistance is multi-faceted and involves multiple pathways in proliferation, apoptosis, metabolism, and the transport of foreign substances. In this review, we dive deeper into hypothesized resistance mechanisms from research during the last decade, with a focus on the cancer types that use taxanes as first-line treatment but frequently develop resistance to them. Furthermore, we will discuss current clinical inhibitors and those yet to be approved that target key pathways or proteins and aim to reverse resistance in combination with taxanes or individually. Lastly, we will highlight taxane response biomarkers, specific genes with monitored expression and correlated with response to taxanes, mentioning those currently being used and those that should be adopted. The future directions of taxanes involve more personalized approaches to treatment by tailoring drug–inhibitor combinations or alternatives depending on levels of resistance biomarkers. We hope that this review will identify gaps in knowledge surrounding taxane resistance that future research or clinical trials can overcome.

show abstract

Section: Taxane Resistance In Ovarian Cancermentioning

confidence: 99%

Mechanisms of Taxane Resistance

Maloney

Hoover

Morejon-Lasso

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…CDK1 expression is elevated in a variety of cancers, often leading to unrestricted proliferation of malignant tumor cells [19][20][21]. PLK1 is a serine threonine kinase that plays a vital role in centrosome maturation, mitotic chromosome separation, and mitosis, and is closely related to the occurrence and development of malignant tumors [22][23][24]. As a kinase, CHEK1 also plays an important role in tumor progression by regulating the cell cycle [25,26].…”

Section: Discussionmentioning

confidence: 99%

Expression and Gene Regulation Network of Metabolic Enzyme Phosphoglycerate Mutase Enzyme 1 in Breast Cancer Based on Data Mining

Wang

Xiong

Hua

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

The metabolic enzyme phosphoglycerate mutase enzyme 1 (PGAM1) is a key enzyme in the glycolysis pathway, and glycolysis is closely related to cancer progression, suggesting that PGAM1 may have important functions in breast cancer. We used sequencing data from the Oncomine database and UALCAN database to analyze the expression of PGAM1 and its influence on the clinicopathological characteristics of breast cancer. LinkedOmics was used to identify genes related to PGAM1 expression, kinases, miRNAs, and transcription factors that were significantly related to PGAM1 through GSEA. cBioPortal was used to identify the alternation frequency and form of PGAM1 in breast cancer. The expression level of PGAM1 in breast cancer was significantly higher than that in normal tissues. Moreover, the expression level of PGAM1 is closely related to the molecular subtype and TP53 mutation status. The expression level of PGAM1 in HER2-positive and triple-negative tumors was significantly higher than that of luminal type. The expression level of PGAM1 in TP53-mutant tumors was higher than that in non-TP53-mutant tumors. In addition, the overall survival of patients with high PGAM1 expression was significantly worse than that of patients with low expression ( P = 0.0077 ). Through GSEA analysis, we found multiple kinases, miRNAs, and transcription factors significantly related to PFKFB4. cBioPortal analysis showed that the mutation rate of PGAM1 in breast cancer was relatively low (4%), and the main form of mutation was high mRNA expression. This study suggests that PGAM1 is a potential diagnostic and prognostic marker in breast cancer. Through data mining, we revealed the potential regulatory network information of PGAM1, laying a foundation for further research on the role of PGAM1 in breast cancer.

show abstract

“…Further large prospective studies are needed to confirm our data. OC represents a group of heterogeneous diseases [35][36][37][38][39][40]; therefore, further investigations are needed to evaluate the applicability of e-nose in detecting various OC types. The new perspective is the implementation of this device in the new collection of exhaled breath samples on a larger population to validate these results and build more robust classification models.…”

Section: Discussionmentioning

confidence: 99%

Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study

Raspagliesi

Bogani

Benedetti

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Diagnostic methods for the early identification of ovarian cancer (OC) represent an unmet clinical need, as no reliable diagnostic tools are available. Here, we tested the feasibility of electronic nose (e-nose), composed of ten metal oxide semiconductor (MOS) sensors, as a diagnostic tool for OC detection. Methods: Women with suspected ovarian masses and healthy subjects had volatile organic compounds analysis of the exhaled breath using e-nose. Results: E-nose analysis was performed on breath samples collected from 251 women divided into three groups: 86 OC cases, 51 benign masses, and 114 controls. Data collected were analyzed by Principal Component Analysis (PCA) and K-Nearest Neighbors’ algorithm (K-NN). A first 1-K-NN (cases vs. controls) model has been developed to discriminate between OC cases and controls; the model performance tested in the prediction gave 98% of sensitivity and 95% of specificity, when the strict class prediction was applied; a second 1-K-NN (cases vs. controls + benign) model was built by grouping the non-cancer groups (controls + benign), thus considering two classes, cases and controls + benign; the model performance in the prediction was of 89% for sensitivity and 86% for specificity when the strict class prediction was applied. Conclusions: Our preliminary results suggested the potential role of e-nose for the detection of OC. Further studies aiming to test the potential adoption of e-nose in the early diagnosis of OC are needed.

show abstract

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma

Cited by 23 publications

References 45 publications

Mechanisms of Taxane Resistance

Mechanisms of Taxane Resistance

Expression and Gene Regulation Network of Metabolic Enzyme Phosphoglycerate Mutase Enzyme 1 in Breast Cancer Based on Data Mining

Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study

Contact Info

Product

Resources

About